Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated pGM169/GL67A Gene Therapy in Cystic Fibrosis
NCT01621867Phase 2Completed
- Sponsor
- Imperial College London
- Start
- May 2012
- Primary completion
- May 2014
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing pGM169/GL67A with Placebo (2 arms). Primary endpoint: Relative change in percent predicted Forced Expiratory Volume in 1-second at 12 months. Started May 2012; status: completed.
02
Drugs
pGM169 + GL67A
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT01621867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621867.